Copy number heterogeneity identifies ER+ breast cancer patients that do not benefit from adjuvant endocrine therapy.

ABSTRACT:

Background

Endocrine therapy forms the backbone of adjuvant treatment for oestrogen-receptor-positive (ER+) breast cancer. However, it remains unclear whether adjuvant treatment improves survival rates in low-risk patients. Low intra-tumour heterogeneity (ITH) has been shown to confer low risk for recurrent disease. Here, it is studied if chromosomal copy-number ITH (CNH) can identify low-risk ER+, lymph-node-negative breast cancer patients who do not benefit from adjuvant endocrine therapy.

Methods

Lymph-node-negative ER+ patients from the observational METABRIC dataset were retrospectively analysed (n = 708). CNH was determined from a single bulk copy-number measurement for each patient. Survival rates were compared between patients that did or did not receive adjuvant end

SUBMITTER: van den Bosch T 

PROVIDER: S-EPMC9519566 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature